prm-151
Recombinant proteinexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
5
Phase 3
2
Phase 4
0
Earliest trial started Jun 1, 2010 (NCT01064817)
Timeline
Indications
Mechanism of action
- Beta amyloid A4 proteinINHIBITOR
APP inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- prm-151
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04552899 | Phase 3 | Jan 29, 2021 | Roche |
| NCT04594707 | Phase 3 | Jan 29, 2021 | Roche |
| NCT02550873 | Phase 2 | Aug 1, 2015 | Promedior, Inc. |
| NCT01981850 | Phase 2 | Oct 1, 2013 | Promedior, Inc. |
| NCT01254409 | Phase 1 | Jan 1, 2011 | Promedior, Inc. |
| NCT01064817 | Phase 2 | Jun 1, 2010 | Promedior, Inc. |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Promedior, Inc. | For profit | 4 | 4 | 2 | 2010 |
| Roche | For profit | 2 | 2 | 1 | 2021 |
2 organizations
Page 1 / 1